Last Updated: 05/06/2026

LoQus23 Therapeutics

Cambridge

Founded 2019

Small molecule inhibitors targeting somatic expansion in neurodegeneration

LoQus23 Therapeutics is a biotechnology company developing oral small molecule inhibitors of DNA mismatch repair for the treatment of Huntington's disease and other triplet repeat expansion disorders.

The company targets MutSβ, a protein complex whose aberrant activity drives somatic expansion and progressive neurodegeneration.

Its lead candidate, LQT-23, was nominated in January 2026 and is advancing towards IND/CTA filing.

Biotech Neurology Drug Discovery

Small Molecule Drugs Neurodegenerative Disease Rare Diseases DNA Damage Response

Is this your company?

Claim this page to receive a verified badge and keep your profile up to date.

Claim page

Company Notes

Member of

Granta Park BioIndustry Association

Similar Companies